ATE241997T1 - Nicht-waessrige protische peptidzubereitungen - Google Patents

Nicht-waessrige protische peptidzubereitungen

Info

Publication number
ATE241997T1
ATE241997T1 AT97930181T AT97930181T ATE241997T1 AT E241997 T1 ATE241997 T1 AT E241997T1 AT 97930181 T AT97930181 T AT 97930181T AT 97930181 T AT97930181 T AT 97930181T AT E241997 T1 ATE241997 T1 AT E241997T1
Authority
AT
Austria
Prior art keywords
peptide preparations
aqueous protic
protic peptide
aqueous
preparations
Prior art date
Application number
AT97930181T
Other languages
English (en)
Inventor
James B Eckenhoff
Cynthia L Stevenson
Sally A Tao
Steven J Prestrelski
Jeremy C Wright
Joe Leonard
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE241997T1 publication Critical patent/ATE241997T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
AT97930181T 1996-07-03 1997-07-01 Nicht-waessrige protische peptidzubereitungen ATE241997T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03
PCT/US1997/010815 WO1998000152A1 (en) 1996-07-03 1997-07-01 Non-aqueous protic peptide formulations

Publications (1)

Publication Number Publication Date
ATE241997T1 true ATE241997T1 (de) 2003-06-15

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930181T ATE241997T1 (de) 1996-07-03 1997-07-01 Nicht-waessrige protische peptidzubereitungen

Country Status (27)

Country Link
EP (1) EP0909175B1 (de)
JP (3) JP2001504802A (de)
CN (1) CN1231256C (de)
AR (1) AR008060A1 (de)
AT (1) ATE241997T1 (de)
AU (1) AU737664B2 (de)
BR (1) BR9710130A (de)
CA (1) CA2259403A1 (de)
CO (1) CO4890854A1 (de)
CZ (1) CZ433898A3 (de)
DE (1) DE69722620T2 (de)
DK (1) DK0909175T3 (de)
ES (1) ES2201306T3 (de)
HU (1) HUP9903942A3 (de)
ID (1) ID19165A (de)
IL (1) IL127769A (de)
MY (1) MY121684A (de)
NO (1) NO323933B1 (de)
NZ (1) NZ333580A (de)
PL (1) PL189402B1 (de)
PT (1) PT909175E (de)
RO (1) RO119862B1 (de)
RU (1) RU2203085C2 (de)
SK (1) SK284490B6 (de)
TW (1) TW491703B (de)
WO (1) WO1998000152A1 (de)
ZA (1) ZA975942B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284490B6 (sk) * 1996-07-03 2005-05-05 Alza Corporation Stabilná nevodná formulácia a spôsob jej prípravy
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2523432C (en) * 2003-04-25 2014-10-28 Microchips, Inc. Solid drug formulation and device for storage and controlled delivery thereof
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
PL2121025T3 (pl) * 2007-01-19 2017-09-29 Hananja Ehf Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
MX2020005326A (es) 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2776055B1 (de) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Behandlungen für magen-darm-erkrankungen
US20130288968A1 (en) * 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (de) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmazeutische Zusammensetzung für eine verzögerte Freisetzung von Lanreotid
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP3372224A1 (de) 2017-03-07 2018-09-12 Alrise Biosystems GmbH Neues system zur kontrollierten wirkstoffabgabe durch mit wasser mischbare lösungsmittel zur herstellung von mit arzneimitteln beladenen mikro- und nanopartikeln
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
CA1336401C (en) * 1987-10-15 1995-07-25 Brian H. Vickery Intranasal administration of polypeptides in powdered form
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
ATE156361T1 (de) * 1992-09-21 1997-08-15 Upjohn Co Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
SK284490B6 (sk) * 1996-07-03 2005-05-05 Alza Corporation Stabilná nevodná formulácia a spôsob jej prípravy

Also Published As

Publication number Publication date
SK179998A3 (en) 1999-05-07
PT909175E (pt) 2003-10-31
ZA975942B (en) 1998-04-16
NZ333580A (en) 2000-06-23
PL330869A1 (en) 1999-06-07
CN1224356A (zh) 1999-07-28
PL189402B1 (pl) 2005-08-31
JP2001504802A (ja) 2001-04-10
EP0909175A1 (de) 1999-04-21
SK284490B6 (sk) 2005-05-05
WO1998000152A1 (en) 1998-01-08
EP0909175B1 (de) 2003-06-04
RU2203085C2 (ru) 2003-04-27
BR9710130A (pt) 1999-08-10
ID19165A (id) 1998-06-28
NO986209L (no) 1998-12-30
CA2259403A1 (en) 1998-01-08
TW491703B (en) 2002-06-21
NO986209D0 (no) 1998-12-30
HUP9903942A3 (en) 2000-07-28
IL127769A (en) 2006-10-31
ES2201306T3 (es) 2004-03-16
AU737664B2 (en) 2001-08-30
MY121684A (en) 2006-02-28
IL127769A0 (en) 1999-10-28
AU3407397A (en) 1998-01-21
JP2008195739A (ja) 2008-08-28
RO119862B1 (ro) 2005-05-30
CZ433898A3 (cs) 1999-04-14
CN1231256C (zh) 2005-12-14
NO323933B1 (no) 2007-07-23
DE69722620D1 (de) 2003-07-10
HUP9903942A2 (hu) 2000-04-28
CO4890854A1 (es) 2000-02-28
JP2010043105A (ja) 2010-02-25
DK0909175T3 (da) 2003-09-29
DE69722620T2 (de) 2004-04-29
AR008060A1 (es) 1999-12-09

Similar Documents

Publication Publication Date Title
ATE241997T1 (de) Nicht-waessrige protische peptidzubereitungen
ATE224199T1 (de) Nicht wässrige polar-aprotische peptidzubereitung
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
NO2010013I1 (no) Rekombinant FSH-CTP
NO982097L (no) Peptider
NO982098D0 (no) Peptider
NO985680D0 (no) Peptidderivater
LV10962A (lv) Jauni peptidi
DE59707298D1 (de) Desodorierende zubereitungen
NO983849D0 (no) Peptidderivater
BR9508433A (pt) Peptídeos
DE69427363T2 (de) Plättchenaggregationsinhibierende peptide
TR199701666A3 (tr) Sismanliga karsi proteinler
ATE235511T1 (de) Vielfältig verzweigte peptidkonstruktionen
NO981052D0 (no) Peptidderivater
NO981051D0 (no) Peptidderivater
NO20012283D0 (no) Koblede peptider
NO992079L (no) ICE-inhiberende peptider
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
SE9602361D0 (sv) Plant proteins/peptides
SE9602803D0 (sv) Recombinant vectors
SE9603282D0 (sv) Recombinant vectors
BR1100812A (pt) Peptìdeo
SE9504467D0 (sv) Peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0909175

Country of ref document: EP